Difference between revisions of "Alpha-2 macroglobulin"
m |
|||
| Line 1: | Line 1: | ||
| − | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | + | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" {infobox header}| '''{{PAGENAME}}''' |
| − | |||
|- | |- | ||
| align="center" colspan="2" bgcolor="#ffffff" | | | align="center" colspan="2" bgcolor="#ffffff" | | ||
| Line 46: | Line 45: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:FXIIIa|*]] | [[Category:FXIIIa|*]] | ||
Latest revision as of 10:25, 10 March 2015
| Substrate peptide name | Alpha-2 macroglobulin |
| Synonyms | - |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular; plasma |
| Swissprot ID | P01023 |
| Reactive glutamines | Q670 |
| Reactive lysines | - |
| Substrate sequence | MCPQLQQYEMHG |
| Structure | No available crystal structure |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:6169549 |
| Notes | |
